肠道菌群
炎症性肠病
医学
法尼甾体X受体
肿瘤坏死因子α
信号转导
药理学
G蛋白偶联胆汁酸受体
疾病
受体
生物
脂肪肝
紧密连接
甘草
炎症
消炎药
克罗恩病
免疫学
透视图(图形)
激酶
肠粘膜
根茎
生物信息学
细胞因子
2型糖尿病
传统医学
中医药
肠易激综合征
表皮生长因子受体
标识
DOI:10.1142/s0192415x26500187
摘要
spp.) is a traditional medicinal plant whose roots and rhizomes possess multiple pharmacological effects. Its core active components include flavonoids, triterpenoids such as glycyrrhizin, and polysaccharides. This paper focuses on licorice's gut microbiota-mediated mechanisms of action. Licorice enhances intestinal barrier integrity and protects gastrointestinal mucosa by upregulating tight junction proteins, activating repair pathways like epidermal growth factor receptor/extracellular regulated protein kinases (EGFR/ERK), and modulating inflammatory signaling via the tumor necrosis factor/nuclear factor-κB (TNF/NF-κB) pathway. At the systemic level, licorice modulates core pathways like Toll-like receptor 4 (TLR4)/NF-κB and farnesoid X receptor/Takeda G protein-coupled receptor 5 (FXR/TGR5) through cross-organ axes such as the gut-immune, gut-liver, and gut-adipose axes to improve conditions including inflammatory bowel disease (IBD), obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic fatty liver disease (NAFLD). However, licorice poses dose-dependent risks which raise concerns regarding its safety. Long-term high-dose use may induce pseudohyperaldosteronism and interactions with multiple medications, and thus necessitates strict clinical dose control. This study reveals the gut microbiota's central mediating role in licorice's efficacy, and thereby provides theoretical support for its rational clinical application.
科研通智能强力驱动
Strongly Powered by AbleSci AI